R Stockbrugger

Plain English
Researchers studied the effectiveness of two tools, EQ-5D and SF-6D, used to measure the quality of life for patients with inflammatory bowel disease (IBD) ten years after their diagnosis. They found that while both tools could identify changes in patients' health related to their condition, they didn't agree well with each other (a correlation score of only 0.58), meaning they might not be interchangeable for cost-effectiveness analyses. This is important because using the wrong tool could affect treatment decisions and healthcare spending. Who this helps: This helps doctors and healthcare policymakers by providing clearer insights into how to measure patient quality of life effectively.

Plain English
This study looked at how often people with chronic inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC), experience symptoms outside of their digestive system, like joint pain or skin issues. Among 1,145 patients tracked over about 10 years, 16.9% developed these extra symptoms, with CD patients being more affected: 20.1% compared to 10.4% in UC patients. This is important because it highlights the need for doctors to monitor and treat these additional health issues in IBD patients. Who this helps: Patients with Crohn's disease and ulcerative colitis.

Plain English
This study looked at how living with inflammatory bowel disease (IBD), specifically ulcerative colitis and Crohn's disease, affects the quality of life of patients across several European countries ten years after their diagnosis. It found that while the overall quality of life for patients was similar to that of the general population, those with ongoing symptoms or who took sick leave reported a lower quality of life. For example, patients experiencing symptoms at the follow-up visit showed significant declines in their quality of life scores, especially in countries like the Netherlands and Norway. Who this helps: This research benefits patients with IBD and their healthcare providers by highlighting factors that may affect their quality of life.

Plain English
This study updated the guidelines for treating Helicobacter pylori (HP) infection in Italy due to growing concerns about antibiotic resistance and changing treatment strategies. A panel of 17 experts reviewed the latest research on diagnosing and treating HP, as well as its connection to gastric cancer, leading to a set of agreed-upon recommendations. These updates are important because they help doctors provide better care for patients infected with HP, ensuring more effective and safer treatment options. Who this helps: This helps patients suffering from Helicobacter pylori infections and related gastrointestinal issues.

Plain English
This study looked at the risk of blood clots in patients with inflammatory bowel disease (IBD) in Europe. Researchers followed 1,145 patients for over 10,000 years and found 19 cases of blood clots, giving a rate of 1.8 cases per 1,000 patient-years. While patients with IBD do have a higher risk of these clots, the risk was lower than some earlier studies suggested, especially for those not hospitalized, although hospitalized patients and those on steroids still faced significant danger. Who this helps: This information benefits doctors treating IBD patients by better informing them about the risk of blood clots.

Plain English
The study focused on the importance of researching digestive and liver diseases in Europe, highlighting how these health issues affect society. It discussed the collaboration between various health organizations and lawmakers, emphasizing the need for funding in upcoming research programs like Horizon 2020, which aims to support such studies from 2014 to 2020. This research matters because understanding and treating gastrointestinal diseases can significantly improve public health and reduce healthcare costs. Who this helps: This benefits patients suffering from digestive and liver diseases.

Plain English
This study looked at the levels of a specific compound (6-TGN) in patients with inflammatory bowel disease (IBD) who are being treated with thiopurine drugs, to see if those levels are related to their health status. Researchers found that 63% of patients experiencing a flare-up had 6-TGN levels below the suggested therapeutic level, compared to 41% of patients in remission. This matters because recognizing low or high drug levels can help doctors adjust treatments for better management of IBD. Who this helps: This helps patients with IBD and their doctors make more informed treatment decisions.

Plain English
This research focuses on the importance of screening for colorectal cancer (CRC) in Europe, emphasizing that it's not yet fully implemented across the region. The authors highlight that the European Union should adopt structured programs for CRC screening and prevention, especially for younger people, and suggest that current practices in countries like the USA and Germany could serve as examples. They argue that integrating cancer prevention into a comprehensive healthcare system is essential for improving health outcomes across Europe. Who this helps: This benefits patients, especially young people and those at risk for colorectal cancer.

Plain English
The Budapest Declaration is a call for improved colorectal cancer (CRC) screening across Europe, addressing that CRC is the second most common cancer in the EU and a leading cause of death. The initiative urges healthcare leaders to implement high-quality screening programs that can significantly reduce cancer deaths, pointing out that these programs could help identify and treat cases early on. If successful, these efforts would ensure that all EU citizens have equal access to life-saving cancer prevention services. Who this helps: This benefits patients at risk of colorectal cancer and healthcare providers involved in their treatment.

Plain English
This review focused on how people view and feel about different methods of screening for colorectal cancer. It found that while various screening techniques are used globally, many patients have negative feelings towards colonoscopy, which could lead to lower participation rates in screening programs. Improving these perceptions matters because it could encourage more people to get screened, ultimately leading to better health outcomes. Who this helps: This benefits patients who may need colorectal cancer screening.

Plain English
Researchers in Ferrara, Italy, studied the first two years of colorectal cancer screenings targeted at people aged 50-69. Out of 38,344 invited, 19,480 (about 50%) took a test for hidden blood in their stools, leading to 1,149 positive results. Ultimately, 91 cancer cases were diagnosed, with 78% found at earlier, more treatable stages (A and B), which is significant compared to only 40% in the general population. Who this helps: This helps patients by increasing detection rates of colorectal cancer at earlier stages.

Plain English
This study looked at the heart and lung issues that can happen during colonoscopy screenings for colorectal cancer in people without major health problems. Among 214 participants, 55.6% experienced low blood oxygen levels, 8.9% had low blood pressure, and 5.6% showed slow heart rates, but no serious complications occurred. These findings are important because they suggest that while minor cardiopulmonary events are common during colonoscopy, they are mostly linked to the procedure itself rather than the patients' health, helping medical teams manage risks better during screenings. Who this helps: This helps doctors and patients undergoing colonoscopy screenings.

Plain English
This study looked at how well different screening tests detect advanced adenomas, which are precursors to colorectal cancer. Researchers compared immunologic fecal occult blood testing (FIT) and pseudosigmoidoscopy to colonoscopy in 329 average-risk people, finding that advanced adenomas were present in 11.6% of subjects. FIT had a low sensitivity of 15.8% for detecting advanced adenomas, while sigmoidoscopy was much better at 73.7%, highlighting that some groups, like women and younger individuals, struggle with lower test accuracy, suggesting the need for more personalized screening methods. Who this helps: This helps patients, particularly women and younger individuals at risk for colorectal cancer.

Plain English
This study looked at how common intestinal and other types of cancer are in people with inflammatory bowel disease (IBD) 15 years after their diagnosis. Researchers followed 681 patients and found that 9.1% (or 62 patients) developed cancer, with most cases being extraintestinal—meaning not in the digestive system. Specifically, only 1.3% had colorectal cancer, while others had different types of cancer, with more intestinal cancers seen in Northern Europe and more extraintestinal cancers in Southern Europe. Who this helps: This research benefits patients with IBD by providing important information about their cancer risk.

Plain English
This study looked at how many hospital staff members participated in and tolerated primary colonoscopy screenings, which are tests for colorectal cancer. Out of 1,090 staff members invited, 447 (41%) agreed to participate. While many found the process somewhat uncomfortable—79.5% reported discomfort during bowel preparation and 21.9% during the procedure—96.3% said they would be willing to do it again. Who this helps: This benefits hospital staff and potentially improves colorectal cancer screening rates in their communities.

Plain English
This study looked at how many people participate in colorectal cancer screening when they receive their first invitation. It found that participation rates vary by method: 47% for a stool test, 42% for a different type of stool test, 35% for sigmoidoscopy, 28% for colonoscopy, and 22% for CT colonography. Understanding what encourages or discourages people from getting screened can help improve these screening programs, addressing both health and cost issues. Who this helps: This benefits patients at risk for colorectal cancer by improving access to screening.

Plain English
This study looked at how a multispecies probiotic affects gut bacteria and bowel habits in patients with chronic obstructive pulmonary disease (COPD) who were receiving antibiotics. Researchers found no significant change in the gut bacteria or bowel movements after taking the probiotic, indicating that antibiotics did not significantly alter the dominant gut bacteria in these patients. This matters because it suggests that the existing imbalance in gut bacteria may limit the effectiveness of probiotics in improving gut health. Who this helps: This research benefits COPD patients who frequently use antibiotics.

Plain English
This study examined the death rates in patients with inflammatory bowel disease (IBD) in the Netherlands from 1991 to 2002, focusing on how many people died and the reasons why. Out of 1,187 patients, 72 died, with higher death rates due to digestive system issues: for those with Crohn's disease, the risk was 7.5 times greater, while for ulcerative colitis it was 3.4 times greater, especially among young patients. This information is crucial for understanding who might need closer medical attention and monitoring based on their age and gender. Who this helps: This helps patients and doctors manage care for people with inflammatory bowel disease.

Plain English
This study examined the health and economic impacts of treatments for ulcerative colitis (UC) and Crohn's disease (CD) in nearly 950 patients over ten years. The research found that 28% of UC patients and 24% of CD patients achieved a state of remission without medication, while a significant portion remained on mild treatment. It revealed that surgery was more likely in CD (20%) compared to UC (8%), and patients who struggled with treatment faced the highest costs, with CD leading to greater total expenses over the decade. Who this helps: This information benefits patients with ulcerative colitis and Crohn's disease, as well as their doctors and healthcare providers.

Plain English
This research paper looks at ways to prevent colorectal cancer (CRC) through medications and other treatments, particularly focusing on a type of drug called cyclooxygenase 2 inhibitors. While these drugs show promise in preventing CRC, they also carry risks of heart problems. The study aims to determine how best to use these preventive measures, either alone or with other strategies, and suggests that more research is needed to refine their application. Who this helps: This benefits patients at risk of colorectal cancer and healthcare providers looking for effective prevention strategies.

Plain English
This study looked at the costs and benefits of using a special medical psychiatric unit (MPU) for patients who have both medical and psychiatric needs. It found that while the MPU led to lower costs for medical services—saving an average of 104 euros per patient—it resulted in higher expenses for psychiatric care and overall hospital stays, totaling an extra 263 euros compared to regular medical wards. This matters because it shows that while patients received better psychiatric care, which is crucial for their treatment, the overall costs increased, indicating that a shift towards outpatient care might be more cost-effective. Who this helps: This helps patients with both psychiatric and medical issues and their healthcare providers.

Plain English
This study looked at how well newly diagnosed Crohn's disease patients in Europe were treated based on established guidelines. It found that 59% of patients with mild-to-moderate disease received the right initial treatment, while 70% of those with severe disease were appropriately treated. This matters because giving the wrong treatment can increase the risk of health complications for patients. Who this helps: This helps patients with Crohn's disease and their doctors.

Plain English
This study looked at how rehabilitation practices for digestive and metabolic diseases have remained mostly the same over the past 25 years. It found that while some quality improvements have been made in the types of rehabilitation offered, the overall organization of these services has not changed much. The authors stress the need for better structures to ensure rehabilitation is acknowledged as important alongside other medical treatments, referencing effective models from countries like Sweden and the Netherlands. Who this helps: This benefits patients with digestive and metabolic diseases by improving their access to effective rehabilitation services.

Plain English
This study looked at how fatigue affects the quality of life for people with inflammatory bowel disease (IBD), focusing on patients in the Netherlands. Researchers found that nearly 40% of patients experienced fatigue even when their disease was not active, and those with active disease reported significantly worse quality of life and fatigue levels. These findings highlight that fatigue is a major concern for IBD patients, regardless of how well their disease is controlled, and doctors should pay attention to it to help improve their patients' well-being. Who this helps: This information helps patients with IBD and their doctors.

Plain English
This study looked at how certain characteristics at the time of diagnosis and other factors influence the progress of inflammatory bowel disease (IBD) over time. Researchers followed 1,187 patients with Crohn's disease or ulcerative colitis for several years and found that 50% of Crohn's patients needed surgery within an average of 7.6 years. The study also pointed out that younger age, smoking, and the location of the disease affect the likelihood of recurrence and the need for surgery. Who this helps: This information is valuable for patients and doctors in understanding prognosis and guiding treatment decisions for IBD.

Plain English
This study looked at a gene called TFPI2, which can be changed in colorectal cancer (CRC). Researchers found that nearly all samples of early and advanced CRC showed changes in this gene, specifically in 97% of adenomas and 99% of other CRC stages. When they tested stool samples, they found that the presence of these changes correctly identified CRC in 76% to 89% of cases while minimizing false positives 79% to 93% of the time. This means that checking for TFPI2 changes in stool could help catch CRC earlier and without invasive procedures. Who this helps: This benefits patients undergoing screening for colorectal cancer.

Plain English
This study looked at the occurrence of Inflammatory Bowel Disease (IBD) in South Limburg, Netherlands, from 1991 to 2002. Researchers found that the rates of Crohn's Disease were 4.84 cases per 100,000 males and 7.58 per 100,000 females, while Ulcerative Colitis rates were 8.51 for males and 6.92 for females, indicating relatively high numbers compared to other European countries. Additionally, patients had an average diagnostic delay of about 5 months for Crohn's Disease and 3 months for Ulcerative Colitis, and no changes in rates or seasonal patterns were observed over the study period. Who this helps: This information benefits patients struggling with IBD, healthcare providers, and researchers looking to understand the disease's patterns.

Plain English
This study focused on creating guidelines for treating Crohn's disease in specific situations like upper gastrointestinal issues, complications outside the digestive system, and the safety of medications during pregnancy and breastfeeding. Experts rated various treatment options on a scale of 1 to 9 and found that medications like infliximab, steroids, and certain digestive aids are safe and appropriate, while medications like methotrexate should always be avoided during pregnancy. These guidelines are important because they help doctors make informed treatment choices, ensuring the safety of both the patient and their developing child. Who this helps: This helps patients with Crohn's disease, particularly those who are pregnant or planning to conceive.

Plain English
This study looked at how a multispecies probiotic affects gut health and bowel movements in healthy people taking the antibiotic amoxycillin. The researchers found that participants taking the probiotic experienced fewer diarrhea-like symptoms, with only 48% reporting such issues compared to 79% in the placebo group. This is important because it shows that taking probiotics can help maintain bowel health during antibiotic treatment, potentially reducing discomfort for patients. Who this helps: This helps patients taking antibiotics, especially those concerned about diarrhea.

Plain English
This study looked at two blood markers, p-ANCA and ASCA, in 432 patients with ulcerative colitis (UC) over ten years to see how they affected the disease's progression. It found that 82% of patients with p-ANCA had disease relapses, compared to 67% of those without it. Patients with p-ANCA were 1.4 times more likely to have a worsening disease course, and those with ASCA had a similar risk of relapses, but neither marker was linked to needing surgery. Who this helps: This research benefits patients with ulcerative colitis by identifying markers that can indicate the likelihood of disease relapses.

Plain English
Researchers studied patients with inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, to see how common spine deformities are and how they relate to bone health. They found that 25% of these patients had vertebral deformities, regardless of their bone density measurements. This is important because it highlights the need for doctors to check for these spine issues, along with bone density, to provide better care for IBD patients. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at how patients with inflammatory bowel disease (IBD) in Europe and Israel prefer to receive information about their condition. Out of 917 participants, 66% relied primarily on their specialists for information, but many felt they weren't informed about recent medical treatments—65% hadn't received any information in the past year. Most patients preferred receiving updates through paper bulletins (76%) and sought information related to new research and treatments, highlighting a need for better communication tailored to individual needs. Who this helps: This helps patients with IBD, as well as their healthcare providers, by improving the way information is communicated.

Plain English
This study looked at patients with ulcerative colitis across Europe to see how many were alive ten years after their diagnosis. Out of 775 patients, 661 were still alive, and the researchers found that the actual number of deaths (73) was very close to what was expected (67), showing that the risk of dying from ulcerative colitis didn't increase over that time. However, there was a notable rise in the risk of dying from lung-related issues, especially among older patients. Who this helps: This benefits patients with ulcerative colitis and their healthcare providers.

Plain English
In a screening program in Ferrara, 776 people with a family history of colorectal cancer were invited for colonoscopies over five years, and 733 agreed to participate. The screenings found that 21.7% had adenomas, which can lead to cancer, and 2.1% had actual colorectal cancer, with most of the cancers detected at an early stage. This is important because early detection can significantly improve treatment outcomes for those at higher risk of developing colorectal cancer. Who this helps: This helps patients with a family history of colorectal cancer and their doctors.

Plain English
This study looked at the safety of a medication called 6-thioguanine, which is used to treat inflammatory bowel disease (IBD) over a long period of time. Researchers followed 13 patients who had been taking a low dose of 6-thioguanine for an average of 36 months and found that none of them developed liver issues known as nodular regenerative hyperplasia. This finding is significant because it suggests that when 6-thioguanine is used in lower doses, it may be safe for IBD patients, unlike fears raised by earlier studies. Who this helps: Patients with inflammatory bowel disease who need long-term medication options.

Plain English
This study looked at genetic markers and antibodies in patients with inflammatory bowel disease (IBD) from different parts of Europe to understand if these factors could explain why IBD is more common in some areas. Researchers found that about 24% of Crohn's disease (CD) patients and 10% of ulcerative colitis (UC) patients had mutations in a specific gene called CARD15, with fewer mutations in Scandinavia compared to the rest of Europe. The findings are important because they show that genetic factors and certain antibodies are linked to the severity of the disease, which can help in understanding and treating patients. Who this helps: This helps patients with IBD by providing insights that could lead to better management and treatment options.

Plain English
This study looked at how often patients with ulcerative colitis needed surgery to remove their colon (colectomy) within the first ten years after being diagnosed. They found that only 8.7% of the patients required this surgery over that time, but rates varied by location: 10.4% in northern Europe and 3.9% in southern Europe. The type of ulcerative colitis also mattered—those with more extensive disease were four times more likely to need surgery compared to those with milder forms. Who this helps: This information benefits patients with ulcerative colitis by providing insights into their treatment options and risks.

Plain English
This study looked at the effects of a medication called low molecular weight heparin (LMWH) on patients with mild to moderate ulcerative colitis, a disease that causes inflammation in the intestines. Researchers tested 29 patients over 8 weeks and found no significant difference in improvement between those taking LMWH and those receiving a placebo; specifically, 11 of 15 patients on LMWH and 9 of 14 on placebo completed the study without noting major benefits from LMWH. This is important because it suggests that LMWH is not more effective than a placebo for treating this condition, which can help doctors make better treatment decisions for their patients. Who this helps: This helps doctors and patients with ulcerative colitis make informed choices about treatment options.

Plain English
This study looked at how certain genetic factors, specifically the Gly908Arg mutation and anti-Saccharomyces cerevisiae antibodies (ASCA), can predict higher healthcare costs for patients with Crohn's disease. Researchers followed 228 patients and found that those with the Gly908Arg mutation had surgical stays averaging 3.5 days per year, costing around 1,580 euros annually, while those without it averaged just 1.5 days with no costs. Similarly, ASCA-positive patients had hospitalization costs of 663 euros compared to none for ASCA-negative patients. Understanding these factors can help identify patients who will likely incur higher medical expenses, allowing for better financial planning. Who this helps: This helps patients and healthcare providers manage Crohn's disease more effectively.

Plain English
This study looked at the effects of the blood thinner low molecular weight heparin (LMWH) on patients with ulcerative colitis (UC) who did not respond to mesalazine, a common treatment. Researchers found that while LMWH reduced the amount of a blood-clotting substance called thrombin in these patients, it did not improve their UC symptoms or overall disease activity. This is important because it shows that even though LMWH has an effect on blood clotting, it doesn't actually help with the main issues related to the disease itself. Who this helps: This information is useful for doctors treating patients with ulcerative colitis who are not responding to standard treatments.

Plain English
This study looked at how Crohn's disease (CD) is treated differently in Northern and Southern Europe by examining 380 patients. They found that patients in Northern Europe were more likely to undergo surgery (about 25%) compared to those in Southern Europe, who were more often treated with medication (around 70%). This difference in treatment suggests that the severity of Crohn's disease may vary based on geographic location, even though the type of disease at diagnosis did not explain why the treatments differed. Who this helps: This research helps patients with Crohn's disease and doctors treating them, highlighting the need for tailored approaches based on where patients live.

Plain English
This study looked at ulcerative colitis (UC) in patients from Europe to see how many experienced a relapse and what factors might increase that risk over ten years. They found that about 67% of patients had at least one relapse during this time, with women having a 20% greater risk than men. Other factors like education level and whether a person smoked also affected relapse rates. Who this helps: This information is valuable for doctors and patients managing ulcerative colitis, particularly for identifying those at higher risk of relapse.

Plain English
This research studied patients with inflammatory bowel disease (IBD) over roughly 10 years to see how often they developed cancer or precancerous conditions. Out of 1,141 patients, 38 (or 3.3%) were diagnosed with a total of 42 cancers, mostly from outside the intestines, with a few having colorectal cancer. Notably, people in northern Europe tended to have more intestinal cancers, while those in the south had more cancers located elsewhere. Who this helps: This information is beneficial for doctors monitoring IBD patients for cancer risks.

Plain English
This study looked at two markers, rectal nitric oxide and fecal calprotectin, to see how they could help assess inflammation in patients with inflammatory bowel disease (IBD). They found that both markers were significantly higher in IBD patients compared to healthy individuals: nitric oxide was much elevated and the fecal calprotectin levels were also increased, with specific measurements showing a strong difference (p <0.001). Understanding these markers is important because they can help doctors evaluate the level of inflammation and potentially improve patient care. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at how different types or "phenotypes" of Crohn's disease affect healthcare costs for patients in Europe. Researchers followed 418 patients over 10 years and found that those with the most severe form, called "penetrating-with-perianal-fistula," had the highest costs, averaging €3,356 per year, while those with the mildest form spent about €1,690 annually. Understanding these costs is important because it helps healthcare providers allocate resources better and improve treatment plans for patients. Who this helps: This benefits patients with Crohn's disease and their doctors.

Plain English
This research paper looks at how probiotics—beneficial live microorganisms—can help with various gastrointestinal and liver diseases, particularly focusing on issues like irritable bowel syndrome, inflammatory bowel disease, and pancreatitis. The findings show that probiotics can be effective for conditions like antibiotic-associated diarrhea and may help reduce symptoms for some patients with irritable bowel syndrome and ulcerative colitis, but more research is needed for other conditions like Crohn's disease and liver disease. This matters because understanding how probiotics work could lead to better treatments for patients suffering from these conditions. Who this helps: This helps patients with gastrointestinal and liver diseases looking for effective treatments.

Plain English
This study looked at how common non-alcoholic fatty liver disease is in people who are severely obese and how weight loss from bariatric surgery affects their liver health. It found that almost all severely obese patients showed signs of liver disease, but after surgery, there was less fat in the liver, although results on inflammation and scarring were mixed. This matters because it highlights bariatric surgery as a hopeful option for improving liver health in obese patients affected by this condition. Who this helps: This helps patients with severe obesity and liver disease.